89bio, Inc. (ETNB): $14.87
Market Cap: $2.21B
Deal value: $2.4B
Roche entered a merger agreement on September 18, 2025, to acquire biotech company 89bio in a deal valued at $2.4 billion, aiming to strengthen its drug pipeline by acquiring an experimental treatment for obesity-related liver disease. The deal would help Roche expand in an area linked to the …